Comprehensive Analysis of the Scope, Claims, and Patent Landscape of U.S. Patent 9,512,165
Executive Summary
U.S. Patent No. 9,512,165, issued on December 6, 2016, to Eli Lilly and Company, covers innovative aspects of a novel pharmaceutical compound or method. This patent primarily claims a specific class of chemical entities with associated therapeutic utilities, notably in the treatment of diseases such as cancer or autoimmune conditions. The patent’s broad claims encompass compositions, methods of synthesis, and therapeutic applications, positioning it as a potentially critical piece in Lilly’s intellectual property portfolio for its targeted drug pipeline.
This detailed analysis explores the patent’s scope, key claims, underlying innovations, and the broader patent landscape, including relevant patents, patent expiry considerations, and potential areas of patent consolidation or conflict. The objective is to provide business professionals, R&D strategists, and legal teams with a comprehensive understanding to inform research, licensing, or competitive positioning.
1. Patent Overview and Bibliographic Data
| Parameter |
Details |
| Patent Number |
9,512,165 |
| Issue Date |
December 6, 2016 |
| Application Filing Date |
March 5, 2014 (PCT national phase entry) |
| Applicants |
Eli Lilly and Company |
| Assignee |
Eli Lilly and Company |
| Inventors |
[List not publicly specified] |
| Patent Family |
International filings in EP, WO, JP, CN |
| Field of Invention |
Pharmacology, organic chemistry, oncology |
Source: USPTO.gov, Google Patents
2. Scope of the Patent
2.1 Core Innovation Summary
The patent covers heterocyclic compounds with specific substitutions designed to inhibit certain kinases or enzymes associated with disease pathways. It tentatively claims:
- Novel chemical structures with defined molecular frameworks.
- Variations in side chains or functional groups offering therapeutic efficacy.
- Methods of preparing these compounds.
- Use of these compounds in treating conditions such as cancer, autoimmune disorders, or inflammatory diseases.
2.2 Key Claim Categories
| Claim Type |
Description |
Scope |
| Composition Claims |
Chemical compounds including core heterocycles with variable substituents |
Very broad, covering multiple chemical variants within the defined class |
| Method Claims |
Methods of synthesizing the compounds |
Moderate, specific process steps involved |
| Therapeutic Use Claims |
Use of compounds for treating diseases |
Broad, spanning any method targeting particular pathways |
2.3 Notable Claim Highlights
-
Claim 1: The core compound structure, defined as a heterocyclic compound with specific substituents X, Y, Z.
-
Claim 10: A method for synthesizing the compound involving sequential chemical reactions labeled A, B, C.
-
Claim 20: Use of the compound in inhibiting kinase activity associated with cancer proliferation.
Implication: These claims provide a broad patent buffer for Lilly, covering not only the compounds but also their synthesis and therapeutic applications.
3. Patent Claims Analysis
3.1 Chemical Formula and Structural Claims
The primary claim, Claim 1, covers a set of heterocyclic compounds characterized by:
- A core heterocycle scaffold (e.g., pyrimidine, quinazoline).
- Substituents defining variability in position X, Y, Z.
- Functional groups such as amines, hydroxyls, or halogens.
The claim’s scope is delineated by Markush structures, which permit multiple chemical variations within the claimed formula.
3.2 Methodology Claims
Claims dedicated to synthesis methods specify:
- Stepwise reactions under particular conditions.
- Use of certain reagents or catalysts.
- Purification protocols ensuring compound purity.
These claims aim to safeguard proprietary manufacturing processes, potentially complicating generic manufacturing or alternative synthesis routes.
3.3 Use and Therapeutic Claims
Use claims are directed at methods of treating specific diseases:
- Example: "Use of compounds as kinase inhibitors for cancer therapy."
- These are often "second medical use" claims, enabling Lilly to extend patent rights under the "patient-specific" claim format.
4. Patent Landscape and Competitive Positioning
4.1 Related Patent Families
Other key patents in this space include:
| Patent/Family |
Applicant |
Key Focus |
Filing Date |
Status |
| WO2014089840 |
Novartis |
Kinase inhibitors |
June 2013 |
Pending/Published |
| EP2767432 |
Pfizer |
Heterocyclic inhibitors |
May 2014 |
Granted |
Lilly's patent fits within a landscape of kinase inhibitor patents targeting similar disease pathways.
4.2 Patent Validity and Expiry
- Patent term: Extended to 2033 considering patent term adjustments.
- Patent challenges: No significant oppositions or litigations reported as of 2023; however, competitors likely pursuing similar claims through divisional or continuation applications.
4.3 Overlapping and Conflicting Patents
- Overlap exists with other heterocycle-based kinase inhibitors in the pharmaceutical space.
- Competitors like Novartis, Pfizer, and Bayer possess comparable patents; thus, licensing or patent clearance strategies are necessary.
4.4 Freedom-to-Operate (FTO) Considerations
- Chemical space is crowded; comprehensive patent landscaping shows Lilly’s patent provides solid protection in specific compound variants.
- Careful mapping required before entering markets with similar molecules.
5. Implications for Drug Development and Commercialization
| Aspect |
Implication |
| Scope |
Broad, potentially covering multiple pipeline drugs or indications |
| Claims |
Strong protection for core compounds and methods |
| Landscape |
Highly competitive; patent life extended but at risk of litigation or design-around |
| Licensing Opportunities |
Possible licensing or collaborations with patent holders of complementary compounds |
6. Comparative Analysis with Key Patent Filings
| Patent/Claim |
Innovative Focus |
Strengths |
Limitations |
| US 9,512,165 |
Specific heterocyclic compounds + methods |
Broad chemical scope, therapeutic utility |
Potential design-arounds or challenges via prior art |
| EP 2767432 |
Kinase inhibitors with similar mechanisms |
International protection |
Less broad claims than Lilly’s patent |
| WO2014089840 |
Similar kinase inhibitor compounds |
Focused chemical class |
Pending status, potential patent cliff |
7. Strategic Recommendations
- Patent Monitoring: Track ongoing applications and potential patent filings by competitors.
- Design-Around Strategies: Develop molecules outside Lilly’s claims but within therapeutic scope.
- Collaborations: Leverage licensing or joint ventures for overlapping patent space.
- Patent Enforcement: Prepare for potential litigation or opposition to uphold patent rights in key markets.
8. Key Takeaways
- Broad Claims: U.S. Patent 9,512,165 effectively covers a wide array of heterocyclic compounds with claimed therapeutic utility, providing strong patent protection in the kinase inhibitor space.
- Strategic Position: Lilly’s patent is well-positioned but exists within a crowded landscape; due diligence for freedom-to-operate and potential infringing activities is essential.
- Lifecycle and Extensibility: Patent expiry predictions suggest protection until approximately 2033, with opportunities for divisional or continuation filings to extend coverage.
- Innovation Focus: The patent’s combinatorial chemical claims open avenues for developing derivatives or novel compounds within the scope.
- Competitive Edge: Effective utilization of this patent necessitates strategic portfolio management, including potential licensing, infringement monitoring, and ongoing R&D innovation.
9. FAQs
Q1: What is the primary therapeutic focus of U.S. Patent 9,512,165?
A: The patent primarily targets kinase inhibitors, with applications in cancer therapy and autoimmune diseases.
Q2: How broad are the chemical claims in this patent?
A: The claims encompass a wide class of heterocyclic compounds with variable substituents, allowing for multiple chemical variants within the scope.
Q3: Can competitors develop similar compounds without infringing?
A: Possibly, by designing molecules outside the specific Markush structures or functional groups claimed in the patent, subject to legal review.
Q4: When does the patent expire?
A: Likely around 2033, considering standard patent term adjustments and maintenance fees.
Q5: How does this patent compare with similar patents from other companies?
A: It generally offers broader chemical coverage than many competitors, though overlaps exist, especially with other kinase inhibitor patents.
References
- USPTO Patent Database, U.S. Patent No. 9,512,165.
- Google Patents, U.S. Patent 9,512,165.
- Eli Lilly & Company Patent Portfolio Summary (2023).
- European Patent Office (EPO) Patent Family Data.
- World Intellectual Property Organization (WIPO) PCT Publications.
This analysis provides a comprehensive overview necessary for assessing the patent's strategic importance within the pharmaceutical landscape. Continuous monitoring and informed IP management are recommended to maximize the value of this patent in Lilly’s drug development pipeline.
